Category Archives: Treatment

Better adherence with once-daily antiretroviral regimens: A meta-analysis

2009

Once-daily regimens of antiretroviral therapy are simpler than other regimens, but whether such regimens are associated with better adherence to treatment is controversial. We performed a meta-analysis of 11 randomized,...

A combination drug of abacavir-lamivudine-zidovudine (Trizivir (R)) for treating HIV infection and AIDS

2009

BACKGROUND: The human immunodeficiency virus (HIV) has become one of the greatest challenges to global public health. In 2007 UNAIDS estimated that 33.2 million people were living with HIV. Currently...

Darunavir: A nonpeptidic antiretroviral protease inhibitor

2007

Background: Protease inhibitors were a major therapeutic breakthrough in the mid-1990s for the treatment of HIV infection, which resulted in improved life expectancy for patients who had failed previous therapies....

Protease inhibitor-containing antiretroviral treatment and tuberculosis: Can rifabutin fill the breach?

2012

OBJECTIVE: To assess how to best manage co-administration of rifabutin (RFB) and human immunodeficiency virus 1 (HIV-1) protease inhibitor (PI) containing antiretroviral treatment (ART). Recommended for initial anti-tuberculosis treatment, rifampicin...

Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults

2005

BACKGROUND: Although antiretroviral treatment (ART) has led to a decline in morbidity and mortality of HIV-infected patients in developed countries, it has also presented challenges. These challenges include increases in...

The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: Systematic review and meta-analysis

2014

Administering drugs as fixed-dose combinations (FDCs) versus the same active drugs administered as separate pills is assumed to enhance treatment adherence. We synthesized evidence from randomized controlled trials (RCTs) about...

Treatment of Kaposi’s sarcoma in HIV-1 infected individuals with emphasis on resource poor settings

2003

BACKGROUND: In many countries, Kaposi’s sarcoma (KS) is the commonest malignancy among individuals infected with the human immunodeficiency virus-1 (HIV) and is a cause of substantial morbidity and mortality. OBJECTIVES:...

Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: A systematic review

2013

INTRODUCTION: HIV infection is associated with vascular dysfunction and adverse cardiovascular outcomes. Our objective was to review the evidence regarding the clinical utility of endothelial activation and coagulation biomarkers for...

Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings

2012

Efavirenz (EFV) is a non-nucleoside widely used as first-line therapy for HIV-1 infection. Most of the research available on EFV comes from trials performed in industrialized countries and only a...

Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness

2013

BACKGROUND: Four clinical trials have shown that oral and topical pre-exposure prophylaxis (PrEP) based on tenofovir may be effective in preventing HIV transmission. The expected reduction in HIV transmission and...

Structured treatment interruptions for the management of HIV infection

2001

Antiretroviral drugs constitute a milestone in the treatment of human immunodeficiency virus (HIV) infection; however, emerging problems limit their long-term use, and an increasing number of patients interrupt the prescribed...

Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature

2002

Knowledge of factors associated with medication adherence could help HIV clinicians to target persons in need of intervention, design these interventions, and help researchers to plan studies of adherence. This...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!